Loading...
About Us 2018-05-29T14:53:35+00:00

OUR VISION

“We will enhance the speed, quality and efficiency of precision oncology research while contributing to the care, treatment experience, and health outcomes of cancer patients worldwide.”

Achieving our vision will require:

  • Our exclusively oncology-focused team including world class oncologists, scientists and research professionals
  • Our novel oncology data repository comprised of real time clinical, quality of life, health outcome, genomic, laboratory, physician notes and cost of care data
  • Our competency analyzing patient treatment patterns, outcomes, quality and cost of care data to deliver real time research, clinical and business intelligence
  • Our approach to building collaborative and effective partnerships with patients, oncology practices, research sites, strategic partners and our sponsors

“In achieving our vision we will set new standards for quality and performance excellence in our industry, thereby delivering outstanding value to patients, our sponsors, our partners, our associates and our shareholders.”

PARTNERSHIPS

Great partnerships are made through hard work. They take time, effort and vision.
We have built great partnerships through complimentary skills, communication and trust.

ASCO CancerlinQ is working to improve the quality and value of care for all patients, connecting cancer care team members, researchers and sponsors with real-world cancer data. Our license allows to deliver de-identified ‘real world’ data from the CancerLinQ Discovery™ product, for use in the design and delivery of Vector Oncology custom data curation, real-world evidence health economics and outcomes research (HEOR) projects, and consulting and data analytic services. Learn more about CancerLinQ.

Precision Health AI is developing the leading artificial intelligence (AI) platform for oncology built on the largest longitudinal clinical oncology dataset to enable the practice of precision medicine for better cancer patient care, getting the right treatment to the right patient at the right time. Insights from Precision Health AI will accelerate cancer-related drug development, trials and real-world evidence for the benefit of the cancer care ecosystem of oncologists, pharmaceutical companies, payers and patients. To learn more, visit www.precisionhealth.ai.

The West Clinic, Methodist Healthcare, and the University of Tennessee Health Science Center joined forces to establish West Cancer Center, a comprehensive, cancer center for the benefit of patients throughout the Mid-South. West Cancer Center is committed to be a world-class leader in oncology research and cancer care; enhance the lives of cancer patients through comprehensive, compassionate care; community outreach and collaborative efforts with community and academic physicians; and to promote understanding and treatment of cancer through innovative training programs, translational research and clinical discovery.

Board of Directors

Dr. Romesh Wadhwani (Chairman)
Dr. Romesh Wadhwani is Chairman and CEO of SymphonyAI, Vector Oncology’s parent company. Dr. Romesh Wadhwani was founder, Chairman and CEO of Aspect Development Group, one of the first “big data” companies, a leader in data/analytics/enterprise software solutions for the supply chain. Ten years after its start in 1991, Aspect was acquired for $9.3B, the largest software deal ever till then. Over the last 15 years, from 2002-2017, Romesh built Symphony Technology Group (STG) from startup to over $2.5B in revenue. STG was organized as a private equity fund in which Romesh was both CEO and Managing Partner. STG has invested $1.6B in capital in 33 platform companies and has created over $10B in enterprise value.

Michael Choukas (Chief Executive Officer)
Michael Choukas was appointed CEO of Vector Oncology in January, 2014, and has worked with the company as a strategic advisor since May, 2012. Prior to joining Vector Oncology, he served as Partner of private equity firm The Watermill Group. Previously, Mike served as President and CEO of Oncopartners, a Latin American oncology development services company, which he founded in 2006. Prior to his work with Oncopartners, he was a member of the leadership team of United Biosource Corporation (UBC) where he served as Executive Vice President of Strategy and Operations and Executive Chairman of the Late Stage Group from 2004 to 2006. In 1996, Mike founded Scirex Corporation and served as Scirex Chairman and CEO until 2003. He held senior leadership positions as Chairman and CEO of Springborn Laboratories, Executive Vice President of Dun and Bradstreet Software and Services, and as a Partner at Bain & Company, where he contributed to the leadership of Bain’s software and M&A practice areas. Mike began his career serving on the staff of the US Senate Committee on Environment and Public Works and then as Legislative Director for US Senator Patrick Leahy. Mike currently serves as Chairman of the Board of Trustees for Vermont Academy, and as an Advisor to the Watermill Group. He holds an MBA from Harvard University and a BA in Economics from Dartmouth College.

Executive Management

Michael Choukas (Chief Executive Officer)
Michael Choukas was appointed CEO of Vector Oncology in January, 2014, and has worked with the company as a strategic advisor since May, 2012. Prior to joining Vector Oncology, he served as Partner of private equity firm The Watermill Group. Previously, Mike served as President and CEO of Oncopartners, a Latin American oncology development services company, which he founded in 2006. Prior to his work with Oncopartners, he was a member of the leadership team of United Biosource Corporation (UBC) where he served as Executive Vice President of Strategy and Operations and Executive Chairman of the Late Stage Group from 2004 to 2006. In 1996, Mike founded Scirex Corporation and served as Scirex Chairman and CEO until 2003. He held senior leadership positions as Chairman and CEO of Springborn Laboratories, Executive Vice President of Dun and Bradstreet Software and Services, and as a Partner at Bain & Company, where he contributed to the leadership of Bain’s software and M&A practice areas. Mike began his career serving on the staff of the US Senate Committee on Environment and Public Works and then as Legislative Director for US Senator Patrick Leahy. Mike currently serves as Chairman of the Board of Trustees for Vermont Academy, and as an Advisor to the Watermill Group. He holds an MBA from Harvard University and a BA in Economics from Dartmouth College.

Dr. Edward Stepanski (PhD, Chief Operating Officer)
Edward Stepanski, PhD, joined Vector Oncology in 2006 after holding many leadership positions in academic medical centers and in national medical societies for over 20 years. Ed brings strong organizational expertise, scientific acumen at the highest academic standards, as well as sensitivity to the needs of oncology from both the business and clinical perspective. Under his leadership, Vector Oncology developed the Health Outcomes and PharmacoEconomics (HOPE) and Pharma Services business units. Ed has co-authored over 100 peer-reviewed papers, book chapters, and books covering many topics in oncology research, sleep medicine, and statistical methodology.

Mark Walker (PhD, Chief Scientific Officer)
Dr. Mark Walker is Vice President of Scientific Affairs for Vector Oncology. His responsibilities include oversight of a wide range of scientific activities including medical writing (protocol development, manuscript preparation, preparation of abstracts and posters), biostatistics (data preparation and analysis for retrospective studies and prospective clinical trials) and oversight of Vector Oncology’s Health Outcomes and PharmacoEconomics (HOPE) group. Dr. Walker came to Vector Oncology from Washington University School of Medicine, where he was a frequent consultant on issues related to research design and statistics, and where he worked clinically with cancer patients as a licensed psychologist at the Siteman Cancer Center. He received his PhD from the University of Memphis, completed internship training at the St. Louis Veterans Affairs Medical Center, and completed a post-doctoral fellowship at Washington University School of Medicine. Dr. Walker has active memberships with the American Psychological Association and the International Society for PharmacoEconomics and Outcomes Research.

Scientific/Clinical Leadership

Dr. Lee S. Schwartzberg (PhD, Scientific and Medical Advisor)
Lee S. Schwartzberg, MD, FACP is the Executive Director of the West Cancer Center in Memphis, TN. He is Professor of Medicine and Chief of the Division of Hematology/Oncology at the University of Tennessee Health Science Center, and Scientific and Medical Advisor at Vector Oncology. Dr. Schwartzberg serves on the NCCN Board of Directors and the NCCN Guidelines Steering Committee. He is a member of the NCCN Breast Cancer Panel, the NCCN Myeloid Growth Factors Panel, and the NCCN Antiemesis Panel. Additionally, Dr. Schwartzberg is a member of the NCCN Oncology Research Program Investigator Steering Committee. Dr. Schwartzberg was the founding editor-in-chief of the journal Community Oncology and currently serves as the editor-in-chief of the Practice Update Oncology website. He serves on the editorial board of both the Journal of Supportive Oncology and The ASCO Post, in addition to serving as a reviewer for many prominent medical journals, including the New England Journal of Medicine and the Journal of Clinical Oncology. His major research interests are new therapeutic approaches to breast cancer, targeted therapy, supportive care and patient reported outcomes. He has published more than 200 research papers during his oncology career. Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology. He maintains a practice in medical oncology focusing on breast cancer.

Mark Walker (PhD, Chief Scientific Officer)
Dr. Mark Walker is Vice President of Scientific Affairs for Vector Oncology. His responsibilities include oversight of a wide range of scientific activities including medical writing (protocol development, manuscript preparation, preparation of abstracts and posters), biostatistics (data preparation and analysis for retrospective studies and prospective clinical trials) and oversight of Vector Oncology’s Health Outcomes and PharmacoEconomics (HOPE) group. Dr. Walker came to Vector Oncology from Washington University School of Medicine, where he was a frequent consultant on issues related to research design and statistics, and where he worked clinically with cancer patients as a licensed psychologist at the Siteman Cancer Center. He received his PhD from the University of Memphis, completed internship training at the St. Louis Veterans Affairs Medical Center, and completed a post-doctoral fellowship at Washington University School of Medicine. Dr. Walker has active memberships with the American Psychological Association and the International Society for PharmacoEconomics and Outcomes Research.

Robert Dufour (Ph.D., Senior Director HEOR)
Robert has 12+ years experienced in the health care industry delivering and managing data analytics and outcomes research. He has a diverse background that includes statistics, research methodology and experience with various disease state. At Vector Oncology, he is responsible to provide direct scientific leadership and oversight of health outcome studies including the development of proposals, protocols, statistical analysis plans, presenting the final results as well as providing leadership to scientific management. Prior to joining Vector Oncology, Robert was a research manager at Humana’s Comprehensive Health Insights where he led multi-disciplinary teams that generated data sets used for research by the department and designed and performed health outcomes studies for biopharmaceutical clients. He is also an experienced SAS programmer who was responsible for data extraction and statistical analyses in previous roles. Several of his studies have been published in journals and presented at various professional conferences. Robert has a BA in psychology from McGill University, a PhD in Psychology from the University of Illinois, Urbana-Champaign and he completed a post-doctoral program at the University of Massachusetts, Amherst.

Karen Skinner (MPH, Director, HEOR)
Karen provides direct scientific leadership and oversight of health outcomes studies utilizing Vector Oncology data resources. Her role includes developing proposals, protocols, statistical analysis plans as well as presenting final results. Her prior experience includes 8 years leading epidemiology research studies. She designed and led custom consulting engagements utilizing secondary data sources and managed a proprietary database. Through this role she participated in all aspects of secondary research including proposal development, study design, comprehensive literature reviews, data analysis, data management and medical writing. Karen holds a MPH with a concentration in Epidemiology from Saint Louis University and a B.S. in Community Health with a minor in Sociology from the University of Illinois, Urbana-Champaign where she graduated with Highest Honors.

Maxine D. Fisher (PhD, Director, Real World Evidence)
Maxine Fisher, PhD, has 10 years of real world analytics expertise and her role includes direct scientific oversight of health outcomes studies as well as design of new processes for conduct of real world research at Vector Oncology. In her previous role as Associate Director of Outcomes Research at HealthCore, Maxine led multi-disciplinary teams to design and deliver real world research for her biopharmaceutical clients. Taking on roles of increasing responsibility over the past decade, her experience includes all aspects of late stage research from developing protocols and statistical analysis plans, medical chart abstraction, data extraction, statistical analysis, medical writing, and oversight of real world research studies. Earlier in her career, Maxine served as Scientific Writer / Intellectual Property Scientist at Sagres Discovery, Medical Writer at the Cancer Information Group, and Postdoctoral Researcher in the Pharmacology Department at the University of Texas Southwestern Medical Center. She holds a PhD, Biochemistry and Molecular Biology from University of Florida and a B.S. Chemistry (Certified, American Chemical Society) from University of Miami. Maxine’s outcomes research studies have been presented at ASCO, SABCS and other conferences and she has authored over 27 publications, 13 of which have been published in peer reviewed journals in the past 9 years.

Junji Lin (Ph.D., MStat., Associate Director, HEOR)
Junji has over five years of hands on experience in health economics and outcomes research (HEOR) and over ten years of experience in conducting biology studies. Her rigorous training in biomedical research and advanced analytical methods provides her a strong background to serve as a tactical and independent researcher. At Vector Oncology, Junji provides scientific oversight and direct leadership of HEOR studies conducted through the use of Vector Oncology data resources. She also consults on statistical methods of other Vector Oncology studies. She takes responsibility for the development of proposals, protocols, statistical analysis plans, and the final disseminations of study results. Junji brings in her industry experience to better serve clients with effective communication and strategic planning. She was previously a Research Scientist at the Real World Evidence (RWE) Center of Excellence at Pharmerit International, where she led claims analyses, retrospective chart reviews, prospective epidemiology studies, and the development and maintenance of the database for data collection encompassing both RWE and Patient Reported Outcomes studies. Junji previously also served as a Manager in Global Health Economics at Amgen, where she developed and executed HEOR strategies and conducted studies to support products in both Nephrology and Hematology/Oncology therapeutic areas. Junji got her professional HEOR training through a joint Analytical Fellowship Program between the Novartis Outcomes Research and Methods Team and Pharmacotherapy Outcomes Research Center at the University of Utah. Prior to joining the industry, Junji got her Master degree in Biostatistics from the department of Public Health at the University of Utah. She also earned her Ph.D. in Molecular Biology from Fudan University, Shanghai, China and was previously a post-doctoral fellow at the School of Medicine at the University of Utah.

Dr. David Schwartz (MD, Consulting Physician)
Dr. Schwartz joined the Department of Radiation Oncology at West Cancer Center in 2016 as Professor and Vice-Chairman. A national academic leader in the treatment of oral and head & neck cancers, Dr. Schwartz is a member of key national research steering committees, including the National Cancer Institute’s Previously Untreated Locally Advanced H&N Cancer Committee, and the Core Committee for H&N Cancer at NRG Oncology. He has served as principal investigator and/or research program core leader for VA MERIT, VA Rehabilitation R&D, NIH, state of Texas CPRIT, private foundation, and industry-funded grants. He has been active in committee leadership at the American Society of Radiation Oncology in the fields of health informatics and cancer disparities. He leads a multidisciplinary software development team to create novel mobile technologies to activate vulnerable patients in their own cancer care.